ライフサイエンスコーパス: sponsor

1 ion to discontinue the study was made by the sponsor.

2 related to study drug by the investigator or sponsor.

3 study was independent of the ATTR-ACT trial sponsor.

4 treatment related by either investigators or sponsor.

5 ed early because of loss of funding from the sponsor.

6 irect electronic query of trial contacts and sponsors.

7 hold for phase III results by small industry sponsors.

8 e III for trials conducted by large industry sponsors.

9 were significantly more likely to have been sponsored.

10 The National Cancer Institute sponsored a clinical trials planning meeting in 2012 to

11 nstitute; and Merck Childhood Asthma Network sponsored a joint workshop to discuss the current state

12 iseases, National Institutes of Health (NIH) sponsored a series of meetings to foster progress toward

13 LD, the American College of Cardiology (ACC) sponsored a stakeholders meeting on October 1 to 2, 2015

14 e gaps, the US National Institutes of Health sponsored a symposium in May 2018 entitled "Obesity and

15 Institute of Allergy and Infectious Diseases sponsored a workshop on drug allergy.

16 of Allergy, Immunology and Transplantation, sponsored a workshop on this emerging tick-related disea

17 Institute of Allergy and Infectious Diseases sponsored a workshop that provided a venue for in-depth

18 Institute of Allergy and Infectious Diseases sponsored a workshop to discuss current understanding an

19 not masked to the investigator, patients or sponsor after the patients were enrolled and randomly as

20 due to security concerns raised by NASA, the sponsoring agency.

21 recommended termination of the trial and the sponsor agreed.

22 Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the

23 Study teams from the sponsor and clinical research organisation, investigator

24 updated compliance data for each individual sponsor and trial at fdaaa.trialstracker.net.

25 ementation: a certain misunderstanding among sponsors and research entities.

26 he statistical programming department of the sponsor, and operationalised through an automated intera

27 Patients, the sponsor, and site personnel were masked to treatment ass

28 eractions among regulatory agencies, payers, sponsors, and investigators and proposes collaboration a

29 recommendations for researchers, advocates, sponsors, and oversight bodies.

30 ial design considerations for investigators, sponsors, and regulators.

31 es that include the large number of industry-sponsored antidepressant trials distort the picture of a

32 e interim, the National Institutes of Health-sponsored "APOL1 Long-term Kidney Transplantation Outcom

33 ites when U.S. National Institutes of Health-sponsored articles (treatment) become freely available f

34 The benefits and risks of the industry-sponsored AS-DCAT from the perspectives of the sponsorin

35 sed public healthcare coverage or a publicly sponsored assistance program to pay for PrEP (12% versus

36 he National Heart, Lung, and Blood Institute-sponsored Asthma Clinical Research Network and AsthmaNet

37 d Other Supplier Public Use File and the CMS-sponsored August through December 2013 Open Payments pro

38 The ongoing National Institutes of Health-sponsored Best Endovascular Versus Best Surgical Therapy

39 y organization, supports research in part by sponsoring biennial research symposia on these disorders

40 e of Allergy and Infectious Diseases (NIAID)-sponsored Bioinformatics Resource Center dedicated to pr

41 CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 2

42 al patient-level data from completed studies sponsored by 13 pharmaceutical companies.

43 one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA

44 This clinical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated explo

45 (-1.99; 95% CI -2.68, -1.31) versus studies sponsored by industry (-0.73; 95% CI -1.00, -0.47) (p va

46 in early stages of development, and few are sponsored by large pharmaceutical companies.

47 king, as well as diet and physical activity, sponsored by multiple community organizations, including

48 Sponsored by New England Biolabs, the Cayman Chemical Co

49 statins was significantly larger for studies sponsored by nonindustry sources (-1.99; 95% CI -2.68, -

50 ble all-payer inpatient health care database sponsored by the Agency for Healthcare Research and Qual

51 Antimicrobial-Resistant Organisms (AROs) was sponsored by the Alberta Ministry of Health to provide e

52 were the focus of a 2-day research symposium sponsored by the American Association for the Study of L

53 an international multidisciplinary committee sponsored by the American College of Radiology and appli

54 e, a hospital-based cancer registry database sponsored by the American College of Surgeons and the Am

55 itled "Diabetes and the Microbiome," jointly sponsored by the American Diabetes Association and JDRF.

56 Publication of this article is sponsored by the American Ophthalmological Society.

57 A multidisciplinary working group sponsored by the Canadian and US government DRI steering

58 andated and publicly reported quality metric sponsored by the Centers for Medicare and Medicaid Servi

59 er 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for th

60 hat participate in the Mini-Sentinel program sponsored by the Food and Drug Administration.

61 me; Bronchial Obstruction and Asthma Cohort; sponsored by the French National Institute of Health and

62 nder the Coordinated Research Project F31004 sponsored by the International Atomic Energy Agency.

63 erventional study in the real-world setting, sponsored by the manufacturer of omalizumab.

64 are the result of this collaborative project sponsored by the MDS Foundation.

65 ls at risk for irAEs at a conference jointly sponsored by the National Cancer Institute, National Ins

66 Concurrently with a workshop sponsored by the National Cancer Institute, we identifie

67 in the Visual System," held in October 2015 sponsored by the National Eye Institute as part of their

68 hy Clinical Research Network (DRCR Network), sponsored by the National Eye Institute, reported the re

69 olled trials (ARMA trial and ALVEOLI trial), sponsored by the National Heart, Lung, and Blood Institu

70 vel data from 4 observational cohort studies sponsored by the National Heart, Lung, and Blood Institu

71 al consultation on bacterial vaginosis (BV), sponsored by the National Institute of Allergy and Infec

72 A single-day workshop sponsored by the National Institute of Diabetes and Dige

73 A workshop sponsored by the National Institute of Diabetes and Dige

74 The goals of this workshop sponsored by the National Institute of Diabetes and Dige

75 A recent workshop sponsored by the National Institute of Diabetes and Dige

76 g Palliative Care in the ICU Project website sponsored by the National Institutes of Health and the C

77 ntermediate Outcome Measures in COPD Study), sponsored by the National Institutes of Health, has esta

78 se 2 multicenter open-label randomized trial sponsored by the National Institutes of Health, simultan

79 al research and what educational initiatives sponsored by the NIH would most likely effect change?

80 We know that clinical trials sponsored by the pharmaceutical industry are likely to e

81 rom this debate: The first will be a meeting sponsored by the Region Languedoc-Roussillon on the deve

82 In December 2014, a workshop sponsored by the subcommittee on collaborative process o

83 A tournament sponsored by the U.S. intelligence community revealed wa

84 It was sponsored by the Universite Laval and the Eunice Kennedy

85 Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by

86 nd Annual Workshop on Cancer Systems Biology sponsored by Tufts University, Boston, Massachusetts, in

87 It is sponsored by University College London (UCL).

88 To examine the extent to which positive NCI-sponsored cancer treatment trials have benefited patient

89 Ps being associated with results of the NIMH sponsored CATIE trial, other SNPs showed weakly positive

90 Industry-sponsored child and adolescent depression trials suffer

91 Industry-sponsored clinical drug studies are associated with publ

92 ipating in the National Institutes of Health-sponsored Clinical Islet Transplantation (CIT) Consortiu

93 National Cancer Institute (NCI)-sponsored clinical trial network studies frequently requ

94 ere treated in the Children's Oncology Group sponsored clinical trial, AAML0122.

95 rt of a larger National Institutes of Health-sponsored clinical trial.

96 t will be used to evaluate proposals for NCI-sponsored clinical trials in which omics tests will be u

97 disease-specific, National Cancer Institute-sponsored clinics.

98 ed prescribing assessments; (3) FDA and TIRF sponsor communications; (4) modifications to the REMS pr

99 onsored AS-DCAT from the perspectives of the sponsoring company and participating sites are discussed

100 n transplant recipients, the goal of the AST-sponsored conference and the consensus documents produce

101 ), FDA evaluations of these reports, and FDA-sponsor correspondence about safety issues.

102 alance between benefit and risk, the study's sponsor decided that they would no longer pursue develop

103 orts are currently being tested in federally sponsored demonstration projects.

104 se their jobs, many will lose their employer-sponsored dental insurance (ESDI).

105 fetal mesencephalic grafts as part of an NIH-sponsored double-blind sham-controlled trial.

106 ssues that is necessary for new reviews, and sponsor DRI-related committees through the National Acad

107 ly received industry "information," attended sponsored "education," and acted as distributors for sim

108 The trials were stopped early after the sponsor elected to discontinue the development of bococi

109 The sponsor elected to terminate this study due to a clearly

110 evelopment and implementation of an industry-sponsored electronic antimicrobial stewardship data coll

111 l, National Heart, Lung, and Blood Institute-sponsored epidemiological cohort study.

112 with publication of outcomes that favor the sponsor, even when controlling for potential bias in the

113 Patients, investigators, and the study sponsor (except members of the interim analysis and prim

114 but millions of dependents for whom employer-sponsored family coverage is unaffordable could remain a

115 ctive encouragement by FDA to clinical trial sponsors for including PROs in drug development programs

116 strate the impact of their research to their sponsors, funders, and fellow academics.

117 reevaluated in Food and Drug Administration-sponsored Gastroenterology Regulatory Endpoints and the

118 Company-sponsored (Genentech or Novartis) studies in DME complet

119 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally execu

120 ial of mepolizumab (substudy of a larger GSK sponsored global phase III trial, MEA115575) where subje

121 ultiple metabolic enzymes, including enzymes sponsoring glycolysis (enolase 1, triosephosphate isomer

122 sity-affiliated programs were more likely to sponsor H1-Bs than independent programs (39.6% vs. 24.4%

123 ndardization method proprietary to the trial sponsor) HDM SLIT-tablet (ALK, Horsholm, Denmark) in adu

124 ntres and five MSM centres within government-sponsored health services), with a single integrated car

125 rance system; offer in parallel a government-sponsored health-care insurance, or gradually expand Med

126 ls with HIV from two very similar government-sponsored healthcare systems that reduced or eliminated

127 he National Heart, Lung, and Blood Institute-sponsored Heart Failure Clinical Research Network.

128 Company-sponsored HIV counselling and voluntary testing with ens

129 misation was computer generated by the study sponsor, implemented by a computerised voice interactive

130 For small industry sponsors, instead, part of the excess remains unexplaine

131 ls younger than 65 years covered by employer-sponsored insurance from 2013 to 2017.

132 zodone dispensing among adults with employer-sponsored insurance or Medicare supplemental plans betwe

133 ctive cohort study of patients with employer-sponsored insurance undergoing common outpatient surgica

134 rganization, $5492 among those with employer-sponsored insurance, $5670 among those with Medigap insu

135 Prospective, single-arm, investigator-sponsored interventional clinical trial.

136 The purpose of this meeting of NCI-sponsored investigators was to identify local institutio

137 nts; allocation was concealed from the study sponsor, investigators, and parents and guardians.

138 The sponsor, investigators, other study site staff (except f

139 The trial sponsor, investigators, participants, and the study staf

140 The sponsor, investigators, site staff, and patients were ma

141 The study sponsor, investigators, staff, and patients were masked

142 Sponsor, investigators, study monitors, patients, and la

143 Sponsors, investigators, study site personnel, and patie

144 Effective enforcement and action from sponsors is needed; until then, open public audit of com

145 using logistic regression models, described sponsor-level reporting, examined trends in reporting, a

146 blic audit of compliance for each individual sponsor may help.

147 les of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That S

148 reported at a National Institutes of Health-sponsored meeting in Bethesda on September 4-6, 2018.

149 s clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled tria

150 A National Cancer Institute (NCI) sponsored, multicenter, phase 3, randomized clinical tri

151 Pharmaceutical companies and other trial sponsors must submit certain trial results to ClinicalTr

152 is paper uses a National Academy of Sciences-sponsored ND dataset comprising 905 injurious and proper

153 ng and more efficient in future academically sponsored NDA filings for PET imaging agents.

154 open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding provided by San

155 Trial sponsor: Nestle Research, Lausanne, Switzerland.

156 estigation used study data from SWOG, an NCI-sponsored network cooperative research group.

157 rs, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium.

158 t 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in

159 there is something different about industry-sponsored non-human animal research, perhaps reflecting

160 mpliant than non-industry, non-US Government sponsors (odds ratio [OR] 3.08 [95% CI 2.52-3.77]), and

161 Amendments Act (FDAAA) of 2007 now requires sponsors of applicable trials to report their results di

162 d by government, universities, philanthropic sponsors of research, major industry players, and collab

163 Developers and sponsors of these candidate products were strongly encou

164 (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects

165 ibute to the publication of research results sponsored or supported by pharmaceutical, medical device

166 was observed for members with FCOIs with the sponsor (OR, 1.79; 95% CI, 0.97-1.46; P = .19 and OR, 3.

167 tly more likely to be compliant than smaller sponsors (OR 11.84 [9.36-14.99]).

168 will be available for external review by the sponsoring organization and any other interested individ

169 will be available for external review by the sponsoring organization and any other interested individ

170 eatures were dissemination of information to sponsor organizations and hospitals, data collection, an

171 guidance will assist practitioners and their sponsoring organizations in preserving their duty of car

172 1988, Iran has operated the only government-sponsored paid living donor (LD) kidney transplant progr

173 110 trials with results, most were industry-sponsored, parallel-design drug studies.

174 nalysis of the National Institutes of Health-sponsored PAREPET trial (Prediction of Arrhythmic Events

175 The sponsor, participants, and investigators were masked for

176 The study sponsor, participants, and investigators were masked to

177 ts, clinical investigators, study staff, and sponsor personnel were masked to the study drug assignme

178 Participants, site personnel, and all study sponsor personnel were masked to treatment allocations.

179 Patients, study investigators, and study sponsor personnel were masked to treatment assignment.

180 Sponsor personnel with direct oversight of the conduct a

181 Participants, investigators, sponsor personnel, and clinical research organisation st

182 Participants, sponsor personnel, investigators, and study site personn

183 icipants, investigators and their staff, and sponsor personnel.

184 the success rate and efficiency of industry-sponsored phase 2/3 clinical trials for adjunctive thera

185 ant (CIT06), a National Institutes of Health-sponsored phase 3, prospective, open-label, single-arm p

186 onto Cancer Therapeutics Evaluation Program-sponsored phase I trials activated between 2000 and 2010

187 To this end, Medicare has sponsored pilot projects to encourage providers to devel

188 The NIDDK-sponsored PIVENS trial (NCT00063622) showed that vitamin

189 th the older PMF2 software and the newer EPA-sponsored PMF 3.0 software were employed.

190 iences (TESS), a National Science Foundation-sponsored program in which researchers propose survey-ba

191 heir antiretroviral treatment using publicly sponsored programs.

192 ge Informatics Platform (PIIP) is an NCI/NIH sponsored project intended for managing, annotating, sha

193 e selection of sunscreen products for an FDA-sponsored proof-of-concept maximal usage clinical trial.

194 ementia trials, and is progressing in a CAMD-sponsored qualification process for use in registration

195 included all published and unpublished Roche-sponsored randomised placebo-controlled, double-blind tr

196 2 National Heart, Lung, and Blood Institute-sponsored randomized clinical trials in infants with sin

197 le National Heart, Lung, and Blood Institute-sponsored, randomized Hybrid Trial (Hybrid Coronary Reva

198 a National Heart, Lung, and Blood Institute-sponsored, randomized, double-blind, placebo-controlled,

199 scussed by researchers, clinicians, industry sponsors, regulators, and representatives from professio

200 y all stakeholders, including investigators, sponsors, regulators, societies, editors, and journals a

201 henotypes is a National Institutes of Health-sponsored repository charged to archive, curate and dist

202 icipants and their parents or guardians, and sponsor representatives advising on trial conduct were m

203 an overall cost-benefit ratio of government-sponsored research is difficult to estimate because the

204 cy as it relates to presentation of industry-sponsored research.

205 Finally, journals, funders, sponsors, research ethics committees, regulators, and le

206 some of the strongest evidence yet of state-sponsored resettlement in the pre-Colonial Andes.

207 e clinical work proceeded, investigators and sponsors responded to specific questions of informed con

208 the new trial designs impact researchers and sponsors responsible for drug development programs, but

209 ions, organization proposals, and government-sponsored reviews.

210 s were assessed by Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Ra

211 up (differences in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Ra

212 dds ratio [OR] 3.08 [95% CI 2.52-3.77]), and sponsors running large numbers of trials were significan

213 staff, clinical adjudication committee, and sponsor's clinical and laboratory personnel were masked

214 Safety data in the sponsor's clinical development safety database from 10 c

215 Additionally, the sponsor's clinical personnel involved in the study were

216 The sponsor's global safety database was analyzed for cardia

217 ur treatment paradigm, it was decided by the sponsor's medical director together with the investigato

218 ents, investigators, site personnel, and the sponsor's study team were masked to treatment allocation

219 personnel, laboratory staff, members of the sponsor's study team, and members of the adjudication pa

220 randomly permuted blocks prepared under the sponsor's supervision.

221 olled onto Cancer Therapy Evaluation Program-sponsored single-agent phase I studies over three decade

222 eviewers, and peer review by members of each sponsoring society.

223 eviewers, and peer review by members of each sponsoring society.

224 s involved in assessment of any outcome, and sponsor staff involved in review or analysis of data wer

225 Patients, investigators, site staff, and sponsor staff were masked to BDP/FF/G and BDP/FF assignm

226 n of the mycobacteriology laboratory staff), sponsor staff, and applicable contract research organisa

227 The sponsor stopped the trial after a prespecified interim a

228 genetic alterations lags, investigators and sponsors struggle with choosing between ideal clinical t

229 bility criteria in National Cancer Institute-sponsored studies are instructive.

230 Pooled sensitivities favored industry-sponsored studies by 6.2 to 34.0 percentage points.

231 While the conclusions of industry-sponsored studies were indeed more enthusiastic than war

232 ifferences between nonindustry- and industry-sponsored studies, such as selective reporting of outcom

233 lity criteria from National Cancer Institute-sponsored studies.

234 e conservative than was seen in non-industry-sponsored studies.

235 Study site personnel, patients, and the sponsor study personnel were masked to the treatment ass

236 ients, investigators assessing outcomes, and sponsor study personnel were masked to treatment assignm

237 ents, investigators, research staff, and the sponsor study team were masked to a patient's treatment

238 Investigators, research staff, sponsor study team, and patients were masked to the iden

239 A Clinical Affairs Committee-sponsored study of ID physicians' positive impact on pat

240 The sponsor, study personnel, and participants were masked t

241 ecommendations arising from an NIH-NHLBI/NCI-sponsored symposium held in November 2012, aiming to ide

242 These ATS-sponsored technical standards describe the equipment, pe

243 analysis, non-inferiority was shown and the sponsor terminated the study.

244 ncurrent nonclinical toxicity study, and the sponsor terminated the study.

245 l Institute of Environmental Health Sciences sponsored the "Workshop for the Development of a Framewo

246 and Digestive and Kidney Diseases of the NIH sponsored the "Workshop on Human Milk Composition-Biolog

247 rnational Liaison Committee on Resuscitation sponsored the COSCA initiative (Core Outcome Set After C

248 fectious Diseases Society of America jointly sponsored the development of this guideline for the trea

249 In March 1966, the Ciba Foundation sponsored the first international, interdisciplinary sym

250 l Institute of Environmental Health Sciences sponsored the Workshop on Mitochondria, Energetics, Epig

251 release of confidential interim data by the sponsor, the academic leadership of the study recommende

252 In addition, the sponsor, the investigators, other study site staff, and

253 fectious Diseases Society of America jointly sponsored this new practice guideline on the treatment o

254 ams; provision of comprehensive PRO plans by sponsors to FDA early in drug development; promotion of

255 e safety needed for human subjects, allowing sponsors to move ahead more quickly with the development

256 sequently contacted corresponding authors or sponsors to provide data.

257 Institute Cancer Therapy Evaluation Program-sponsored trial assessed the tolerability and efficacy o

258 A prospective, open-label, investigator-sponsored trial of intravitreal aflibercept for polypoid

259 st National Heart, Lung, and Blood Institute-sponsored trial of postconditioning in the United States

260 This National Institute of Health-sponsored trial will investigate oral iron polysaccharid

261 rebral edema deaths during a separate pharma-sponsored trial.

262 Industry-sponsored trials (69.6% of phase 3 trials) were signific

263 leteness of journal publications of industry-sponsored trials on the effectiveness and harms of rhBMP

264 In contrast to the industry-sponsored trials, depression trials funded by the Nation

265 h on medical devices, problems with industry-sponsored trials, the lack of head-to-head trials of new

266 lizumab of 200 mg every 3 weeks in all Merck-sponsored trials.

267 of all resistance information available from sponsors' trials as a tool to inform the HCV drug develo

268 rial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluatin

269 CTTI recommends that sponsors use a central IRB and discuss trial endpoints w

270 gression, with the Movement Disorder Society-sponsored version of the Unified Parkinson's Disease Rat

271 ID-19 pandemic but also an outbreak of state-sponsored violence.

272 to treatment assignment; however, the study sponsor was masked to treatment assignment until databas

273 ltrials.gov, Google Scholar, PubMed, Embase, sponsor websites, and direct electronic query of trial c

274 Participants, caregivers, investigators, and sponsor were all blinded to group assignment.

275 cipants, investigators, study staff, and the sponsor were masked to group assignment until all partic

276 ts, investigators, their site personnel, and sponsor were masked to group assignment.

277 Participants, investigators, and trial sponsor were masked to group assignment.

278 Patients, investigators, and the sponsor were masked to PD-L1 expression status.

279 pendent radiology committee members, and the sponsor were masked to PD-L1 expression status.

280 Patients, site study staff, and sponsor were masked to study treatment.

281 rs, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score

282 Patients, study personnel, and the sponsor were masked to the treatment group assignment.

283 Site investigators, patients, and the sponsor were masked to treatment allocation during the s

284 Patients, investigators, and the study sponsor were masked to treatment assignment.

285 Patients, study personnel, and the sponsor were masked to treatment assignment.

286 tors, patients, data analysts, and the trial sponsor were masked to treatment assignment.

287 ts, investigators, study site staff, and the sponsor were masked to treatment assignment.

288 Site staff, patients, and the sponsor were masked to treatment assignment.

289 Patients, physicians, study staff and the sponsor were masked to treatment group allocation.

290 All participants, investigators, and the sponsor were masked to treatment group assignment.

291 Patients, investigators, and sponsors were blinded to the treatment.

292 were extracted from the registry, and trial sponsors were contacted for additional information, as n

293 a publication could not be identified, trial sponsors were contacted to confirm publication status.

294 v, publications, or corresponding authors or sponsors were excluded.

295 Patients, investigators, and trial sponsors were masked to treatment allocation.

296 Industry sponsors were significantly more likely to be compliant

297 epared by personnel from the study's funding sponsor who were not involved with the conduct of the st

298 he National Heart, Lung, and Blood Institute-sponsored WISE (Women's Ischemia Syndrome Evaluation) st

299 Institute of Allergy and Infectious Diseases-sponsored Working Group and the European Academy of Alle

300 A Water Research Foundation-sponsored workshop gathered experts from across the Unit